What Is Cagrilintide?

Lau et al. (Lancet): Phase 2 RCT showing cagrilintide 4.5mg weekly achieved 10.8% weight loss vs 3.0% placebo at 26 weeks, with acceptable safety profile.

Frias et al. (Lancet): CagriSema combination achieved 15.6% weight loss at 32 weeks in type 2 diabetes patients — superior to either agent alone.

Review of amylin's role in energy homeostasis and why dual amylin-calcitonin receptor agonists like cagrilintide represent a new weight loss mechanism distinct from GLP-1.

A 2026 randomized controlled trial demonstrated that co-administering cagrilintide and semaglutide resulted in a significantly greater bodyweight reduction (-18.4%) compared to semaglutide alone (-11.9%) over 68 weeks in East Asian adults with overweight or obesity.

Next-generation multi-receptor agonists and amylin analogs demonstrated weight reductions of up to 24% and improved metabolic outcomes beyond traditional GLP-1 therapies. A 2026 review investigated these emerging treatments, highlighting a shift toward integrated neuroendocrine and body-composition-focused disease modification.

A 2026 review found that childhood obesity significantly increases cardiovascular risks, and demonstrated that emerging therapies like retatrutide and oral GLP-1 agents are currently under clinical evaluation to improve weight management adherence.

Structured, mechanism-based nutritional counseling may mitigate gastrointestinal adverse events and improve adherence in patients using incretin-based anti-obesity medications, a 2026 review found. The researchers provided a pragmatic framework combining pharmacology with clinical nutrition to optimize tolerability and patient outcomes.

A 2026 in vitro study found that tirzepatide promoted sustained improvements in skeletal muscle mitochondrial respiration under both healthy and lipotoxic conditions. In contrast, semaglutide and cagrilintide demonstrated transient reductions in mitochondrial function that resolved after five days.

A 2026 meta-analysis demonstrated that Cagrisema produced significantly greater weight loss than semaglutide, while cagrilintide monotherapy yielded comparable results. The study found the combination therapy offered superior efficacy with a similar overall safety profile, despite slightly higher rates of nausea.

A 2026 meta-analysis found that CagriSema demonstrated superior reductions in body weight, waist circumference, and systolic blood pressure compared to semaglutide monotherapy or placebo. However, the dual therapy was also associated with a higher frequency of gastrointestinal adverse events.

A 2026 review found that second-generation long-acting amylin receptor agonists, including cagrilintide, demonstrate significant efficacy in clinical trials investigating obesity and type 2 diabetes. These peptides were shown to induce satiety and promote weight loss, particularly alongside GLP-1 receptor agonists.

A 2026 preclinical study demonstrated that the amylin receptor agonists pramlintide, cagrilintide, and KBP-066 undergo N- and C-terminal degradation to yield stable metabolites. These findings established a validated LC-MS/MS detection approach for monitoring these peptides in anti-doping programs.

A 2026 review found that bariatric surgery remains a crucial obesity intervention alongside GLP-1 receptor agonists. Researchers demonstrated that real-world limitations of pharmacotherapy, including cost and tolerability, necessitate the continued integration of surgical strategies for sustainable weight management.

Clinical studies demonstrated that amylin analogs improved glycemic control and induced weight loss in individuals with diabetes and obesity, according to a 2026 review. The review found that combining these peptides with GLP-1 receptor agonists yielded synergistic weight loss exceeding 15%.

Novel peptide agents, including tirzepatide, survodutide, and retatrutide, are being investigated as additions to standard therapies for managing diabetes and chronic kidney disease. A 2025 review highlighted these emerging treatments aimed at slowing renal disease progression and reducing cardiovascular risk.

A 2026 review found that peptide-based amylin receptor agonists demonstrate enhanced pharmacokinetics, synergy with GLP-1 agonists, and favorable impacts on weight regulation. These agents are being investigated for potential disease-modifying effects beyond standard weight loss.

A 2025 review found that GLP-1 receptor agonists can exacerbate protein and micronutrient deficiencies in post-bariatric patients undergoing body contouring surgery. Researchers emphasized that tailored perioperative nutritional optimization is necessary to mitigate impaired wound healing risks.

A 2026 Phase III randomized controlled trial demonstrated that CagriSema (semaglutide and cagrilintide) significantly reduced systolic and diastolic blood pressure compared to placebo in adults with overweight or obesity. The study found that 63% of treated participants reached blood pressure targets at 68 weeks.

CagriSema demonstrated superiority over subcutaneous amycretin in a 2025 meta-analysis of seven randomized controlled trials, which also identified an optimal 10-20 mg therapeutic window for amycretin to balance efficacy and tolerability.

A 2026 review hypothesized that combining amylin-based therapies with renin-angiotensin system (RAS) inhibitors redirects amylin-induced RAS activation toward a protective alternative pathway. Researchers proposed this mechanism to explain the substantial blood pressure reductions observed in recent clinical trials.